The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
FineR.L.FogelmanD.R.SchreibmanS.M.The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol.2008; 61(1): 167–175.
2.
DakikH.K.MoskovicD.J.CarlsonP.J.The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol.2012; 69(2): 425–430.
3.
De Jesus-AcostaA.J.OliverG.R.BlackfordA.A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol.2012; 69(2): 415–424.
4.
HillM.E.LiX.KimS.A phase I study of the bio-modulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemother Pharmacol.2011; 67(3): 511–517.
5.
AmarantidisK.HouhouliK.PapatheodorouK.A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors. Oncol Res.2006; 16(6): 281–287.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology - Pancreatic adenocarcinoma. V.1.2012. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed November 14, 2011.
11.
CohenM.R.SmetzerJ.Dosing error with new Taxotere concentration. ISMP Medication Safety Alert! March 24, 2011. Volume 16, Issue 6.
12.
SavareseD.TaplinM.E.HalabiS.HarsV.KreisW.VogelzegangN.A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B trial 9780. Semin Oncol.1999; 26(5 suppl 17): 39–44.
13.
TemperoM.PlunkettW.Ruiz Van HaperenV.Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol.2003; 21(18): 3402–3408.
BaschE.PrestrudA.A.HeskethP.J.American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2011. J Clin Oncol.2011; 29: 4189–4198.
GelingO.EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
20.
TerreyJ.P.AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
21.
CarmichaelJ.KeizerH.J.CupissolD.MilliezJ.ScheidelP.SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
22.
de WitR.de BoerA.C.vd LindenG.H.StoterG.SparreboomA.VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
23.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
24.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
ZanottiK.M.MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety.2001; 24(10): 767–779.
27.
SmithT.J.KhatcheressianJ.LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
MarounJ.A.AnthonyL.B.BlaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
30.
BensonA.B.AjaniJ.A.CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
31.
GressettS.M.StanfordB.L.HardwickeF.Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Tract.2006; 12(3): 131–141.
32.
DelalogeS.LlombartA.Di PalmaM.Gemcitabine in patients with solid tumors and renal impairment. Am J Clin Oncol.2004; 27(3): 289–293.
